A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients With Early-Stage Resectable Lung Adenocarcinoma
The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.
• The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study.
• The participant is ≥22 years of age on the day of signing informed consent.
• The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection.
• The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy.
• The participant with multiple nodules has one nodule that meets the criteria.
• The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.